Anxiety in Children and Adolescents: Screening
October 11, 2022
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
By Meera Viswanathan, PhD; Ina F. Wallace, PhD; Jennifer Cook Middleton, PhD; Sara M. Kennedy, MPH; Joni McKeeman, PhD; Kesha Hudson, PhD; Caroline Rains, MPH; Emily B. Vander Schaaf, MD, MPH; Leila Kahwati, MD, MPH
The information in this article is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This article is intended as a reference and not as a substitute for clinical judgment.
This article may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
This article was published online in JAMA on October 11, 2022 (JAMA. 2022;328(14):1445-1455. doi:10.1001/jama.2022.16303).
Importance: Anxiety in children and adolescents is associated with impaired functioning, educational underachievement, and future mental health conditions.
Objective: To review the evidence on screening for anxiety in children and adolescents to inform the US Preventive Services Task Force.
Data Sources: PubMed, Cochrane Library, PsycINFO, CINAHL, and trial registries through July 19, 2021; references, experts, and surveillance through June 1, 2022.
Study Selection: English-language, randomized clinical trials (RCTs) of screening; diagnostic test accuracy studies; RCTs of cognitive behavioral therapy (CBT) or US Food and Drug Administration–approved pharmacotherapy; RCTs, observational studies, and systematic reviews reporting harms.
Data Extraction and Synthesis: Two reviewers assessed titles/abstracts, full-text articles, and study quality and extracted data; when at least 3 similar studies were available, meta-analyses were conducted.
Main Outcomes and Measures: Test accuracy, symptoms, response, remission, loss of diagnosis, all-cause mortality, functioning, suicide-related symptoms or events, adverse events.
Results: Thirty-nine studies (N = 6065) were included. No study reported on the direct benefits or harms of screening on health outcomes. Ten studies (n = 3260) reported the sensitivity of screening instruments, ranging from 0.34 to 1.00, with specificity ranging from 0.47 to 0.99. Twenty-nine RCTs (n = 2805) reported on treatment: 22 on CBT, 6 on pharmacotherapy, and 1 on CBT, sertraline, and CBT plus sertraline. CBT was associated with gains on several pooled measures of symptom improvement (magnitude of change varied by outcome measure), response (pooled relative risk [RR], 1.89 [95% CI, 1.17 to 3.05]; n = 606; 6 studies), remission (RR, 2.68 [95% CI, 1.48 to 4.88]; n = 321; 4 studies), and loss of diagnosis (RR range, 3.02-3.09) when compared with usual care or wait-list controls. The evidence on functioning for CBT was mixed. Pharmacotherapy, when compared with placebo, was associated with gains on 2 pooled measures of symptom improvement—mean difference (Pediatric Anxiety Rating Scale mean difference, −4.0 [95% CI, −5.5 to −2.5]; n = 726; 5 studies; and Clinical Global Impression–Severity scale mean difference, −0.84 [95% CI, −1.13 to −0.55]; n = 550; 4 studies) and response (RR, 2.11 [95% CI, 1.58 to 2.98]; n = 370; 5 studies)—but was mixed on measures of functioning. Eleven RCTs (n = 1293) reported harms of anxiety treatments. Suicide-related harms were rare, and the differences were not statistically significantly different.
Conclusions and Relevance: Indirect evidence suggested that some screening instruments were reasonably accurate. CBT and pharmacotherapy were associated with benefits; no statistically significant association with harms was reported.
Anxiety is a common condition in children and adolescents. The 2020 National Survey of Children’s Health estimated that 7.8% of children aged 3 to 17 years had a current anxiety disorder; 0.7% had severe anxiety.1 Longitudinal studies of anxiety disorders suggest that early anxiety may lead to an increased risk for secondary depression.2-4 In addition, childhood anxiety often interferes with social, emotional, and academic development5,6 that can result in substance abuse, dependence, or both; suicide; educational underachievement; and functional impairment.7,8 The rationale for routine screening is to identify undiagnosed youth who may benefit from effective treatment for anxiety disorders. This systematic review evaluated the evidence on screening for anxiety in children and adolescents to inform a new recommendation by the US Preventive Services Task Force (USPSTF).
Scope of Review
Data Sources and Searches
PubMed, the Cochrane Library, PsycINFO, CINAHL, and ClinicalTrials.gov were searched for English-language articles (eMethods in the JAMA Supplement). Searches for treatment of anxiety were limited to articles published from January 1, 2017, to July 19, 2021, because evidence from prior to 2017 was identified from an existing comprehensive Agency for Healthcare Research and Quality (AHRQ) review.11 Reference lists of pertinent articles and studies suggested by reviewers were also evaluated. Article alerts and targeted searches of journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and the related USPSTF recommendation were used as part of ongoing surveillance. The last surveillance was conducted on June 1, 2022.
Two investigators independently reviewed titles, abstracts, and full-text articles using prespecified inclusion criteria for each key question (eMethods in the JAMA Supplement); disagreements were resolved by discussion or by a third reviewer. English-language studies that included children and adolescents 18 years or younger, were of fair or good methodological quality, and were conducted in countries categorized as very highly developed by the 2018 United Nations Human Development Index were eligible.12 For screening, studies that included unselected participants without known anxiety were eligible. For treatment, selection was restricted to studies of participants diagnosed with at least 1 anxiety disorder (ie, generalized anxiety disorder, social anxiety disorder, panic disorder, agoraphobia, separation anxiety disorder, and selective mutism). For studies of nonpharmacological interventions, inclusion was restricted to cognitive behavioral therapy (CBT), the most common therapy.
Eligible pharmacotherapy interventions included agents approved by the US Food and Drug Administration for pediatric use (eg, clonidine, duloxetine, fluoxetine, escitalopram, sertraline, fluvoxamine). Interventions were required to be relevant to or referable from primary care. Eligible outcomes for benefits of screening and treatment included anxiety symptoms measured by validated instruments, clinical response, or remission; all-cause mortality; quality of life measured using validated scales or instruments; and functioning measured by validated scales, missed days of school, or sleep-related outcomes. Eligible harms of treatment included treatment avoidance, deterioration in patient-clinician relationship, labeling or stigma, unnecessary treatment, serious adverse effects, withdrawal due to adverse effects, and suicidality.
Data Extraction and Quality Assessment
For each included study, 1 reviewer abstracted relevant study characteristics and outcomes into a structured form. A second reviewer checked all data for completeness and accuracy. Methodological quality ratings for included studies from a prior AHRQ evidence review on anxiety treatment in youth11 were spot checked and carried forward. All other studies were rated dually and independently using predefined criteria established by the USPSTF (eMethods in the JAMA Supplement) and others.11,13-16 Disagreements in study quality ratings were resolved through discussion or by a third senior reviewer. Detailed study quality assessments are provided in eTables 1 through 6 in the JAMA Supplement.
Data Synthesis and Analysis
Data were synthesized in tabular and narrative forms. When at least 3 similar studies were available, a quantitative synthesis was performed using random-effects models with the inverse-variance weighted method of DerSimonian and Laird in Comprehensive Meta-Analysis (version 3.3) software to generate pooled estimates of effect.17 The I2 statistic was calculated to assess statistical heterogeneity in effects.18 Significance testing was based on the exclusion of the null value by the 95% CI around the pooled estimate; all testing was 2-sided.
The strength of evidence was assessed as high, moderate, low, or insufficient using methods developed for the USPSTF and the AHRQ Evidence-based Practice Center program.9,19 Two senior reviewers independently developed initial strength of evidence assessments; disagreements were resolved through discussion or input of a third senior reviewer.
Thirty-nine studies (N = 6065) in 50 publications were eligible (Figure 2), including 10 studies reporting on screening test accuracy21-30 and 29 randomized clinical trials (RCTs) reporting on treatment interventions.31-70 The results in this publication focus on pooled analyses when available. Additional results are available in the full report.10 A list of full-text articles that were screened but excluded is provided in the JAMA Supplement (List of Excluded Studies).
Benefits of Screening
Key Question 1. Do anxiety screening programs in primary care or comparable settings result in improved health outcomes in children and adolescents?
No trial directly assessed the benefits of screening children or adolescents for anxiety in the primary care setting.
Accuracy of Screening Instruments
Key Question 2. Do instruments to screen for anxiety accurately identify children and adolescents with anxiety in primary care or comparable settings?
Ten fair-quality studies assessed the accuracy of 12 different screening instruments for detecting anxiety21-30 (n = 3260) (eTables 7 and 8 in the JAMA Supplement). Some studies assessed multiple instruments, some instruments were examined in multiple studies, and some studies examined instrument versions for children, adolescents, or both or included parents, youth, or both as respondents. Five studies21,23,28-30 examined instrument accuracy for detection of social anxiety disorder, 3 studies24-26 for generalized anxiety disorder, 2 studies24,27 for panic disorder, 1 study25 for separation anxiety disorder, and 1 study for global anxiety not specific to any given disorder.22
The prevalence of anxiety disorders in included studies, based on diagnostic clinical interviews, ranged from 2.5% to 24%. Table 1 provides the sensitivity and specificity by screening instrument (additional detail is provided in eTable 9 in the JAMA Supplement). Across all instruments and respondents, sensitivity ranged from 0.34 to 1.00 and specificity ranged from 0.47 to 0.99.
Findings Within Age Groups
Seven studies of adolescents (mean age, 14.8 years) reported on 8 instruments,21,23,24,27,28,30 and 4 studies on school-aged children and adolescents aged 7 to 17 years (mean age, 11.0 years) reported on 7 instruments.21,22,71,72 No study included children younger than 7 years.
Only 1 study21 reported results for adolescents and children separately for the same instruments; these results did not suggest consistent differences in sensitivity and specificity by age of the youth, and variations in instruments and thresholds may explain differences in results. Across instruments and conditions reported in other included studies, differences in reported accuracy between studies on adolescents alone vs studies including both adolescents and children did not suggest age-related patterns (eTable 9 in the JAMA Supplement).
Harms of Screening
Key Question 3. What are the harms associated with screening for anxiety in primary care or comparable settings in children and adolescents?
No trial directly assessed the harms of screening children or adolescents for anxiety in the primary care setting.
Benefits of Treatment
Key Question 4. Does treatment (cognitive behavioral therapy or pharmacotherapy) of anxiety result in improved health outcomes in children and adolescents?
Benefits of treatment for anxiety are summarized in Table 2.
Twenty-nine RCTs (described in 40 articles) of good or fair quality were eligible (n = 2805).31-70 All studies are new to this report because this topic has not been addressed previously by the USPSTF. Detailed study, population, and intervention characteristics and results are reported in eTable 10 in the JAMA Supplement; detailed outcomes are reported in eTables 11 through 19 in the JAMA Supplement; and results from meta-analyses are provided in eFigures 1 through 17 in the JAMA Supplement. Sixteen studies enrolled children with any type of anxiety disorder.31,43,45,46,52,54-59,62,64,66-68 The most common primary diagnoses in these studies were social anxiety disorder and generalized anxiety disorder. Of the studies requiring specific anxiety disorders for trial eligibility, 5 required generalized anxiety disorder,41,53,63,65,70 4 required social anxiety disorder,42,47,60,69 2 required selective mutism,44,61 and 2 required either generalized anxiety disorder, social anxiety disorder, or separation anxiety disorder.32-40,48-51 Nine studies set a threshold for severity.41,48-50,57,58,60,62,63,65 Nine of 29 studies had a majority of male participants.48-52,55-58,63,64
The mean age of enrolled populations ranged from 4.1 to 17.4 years. Three studies focused on early childhood (ages 3-7 years57,66,68), 11 focused on school-aged children (6-14 years44,47,52,55,56,58,60,64,65,67,69), 11 spanned childhood and adolescence,31-41,45,46,48-51,53,59,61-63 and 4 focused solely on adolescence.42,43,54,70 Results below are summarized overall and then by age group when available.
Twenty-two RCTs evaluated CBT,31,42-47,52-60,64-67 6 evaluated pharmacotherapy,41,48-51,61-63,70 and 1 evaluated CBT, sertraline, and CBT plus sertraline separately.32-40 The results below focus on CBT and pharmacotherapy; detailed results for combination therapy are available in the full report.10
Reported outcomes included (1) anxiety symptoms, (2) clinical response or remission, and (3) functioning. CBT was associated with clinically important and statistically significant benefits on several pooled estimates of effect for end-of-treatment measures of anxiety symptoms (Table 2). These measures included the clinician severity rating on the Anxiety Disorders Interview Schedule (mean difference, −2.01 [95% CI, −2.74 to −1.29]; n = 579; 11 RCTs31,43-45,53,54,57,59,65,68,73), the child-rated Spence Children’s Anxiety Scale (SCAS) (mean difference, −7.81 [95% CI, −10.99 to −4.63]; n = 668; 9 RCTs31,43,45,52,54-56,59,65), the parent-rated SCAS (mean difference, −6.06 [95% CI, −9.58 to −2.56]; n = 652; 9 RCTs31,43,45,52,54-56,59,65), and the Revised Children’s Manifest Anxiety Scale (mean difference, −3.08 [95% CI, −5.91 to −0.24]; n = 241; 3 RCTs56,64,67). For pharmacotherapy, pooled estimates of effect suggested clinically important and statistically significant improvements for symptom improvement (Pediatric Anxiety Rating Scale mean difference, −4.0 [95% CI, −5.5 to −2.5]; n = 726; 5 RCTs;32-41,48-51,62,70 Clinical Global Impression–Severity scale mean difference, −0.84 [95% CI, −1.13 to−0.55]; n = 550; 4 RCTs32-41,63,70) (Table 2).
CBT was also associated with a favorable clinical response (pooled relative risk [RR], 1.89 [95% CI, 1.17 to 3.05]; n = 606; 6 RCTs32,44,46,54,57,66), increased remission (pooled RR, 2.68 [95% CI, 1.48 to 4.88]; n = 321; 4 RCTs31,43,56,59), loss of any anxiety diagnosis (pooled RR, 3.09 [95% CI, 1.98 to 4.80]; n = 1414; 15 RCTs31,43,45,46,52-54,58,59,64-68), and loss of the primary anxiety diagnosis (pooled RR, 3.02 [95% CI, 1.84 to 4.95]; n = 1079; 13 RCTs31,43-46,52-54,58-60,65,68,73). Pharmacotherapy was also associated with a favorable clinical response (pooled RR, 2.11 [95% CI, 1.58 to 2.98]; n = 370; 5 RCTs32-40,61-63,70), but results from 3 studies were inconsistent for remission.32-41,63 Regarding functioning, both CBT and pharmacotherapy were associated with statistically significant improvement on the Children’s Global Assessment Scale (mean difference for CBT, 7.54 [95% CI, 2.84 to 12.23]; n = 811; 8 RCTs;32-40,44,46,53,54,58,65,68 mean difference for pharmacotherapy, 5.14 [95% CI, 3.21 to 7.08]; n = 551; 3 RCTs32-41,62), whereas the evidence on other measures was not statistically significant.
Findings Within Age Groups
Three studies enrolled children aged 3 to 7 years57,66,68 and 4 studies enrolled only adolescents aged 13 to 20 years.42,43,54,70 The remaining studies focused on school-aged children aged 5 to 14 years (12 studies44,45,47,55,56,58,60,64,65,67,69) or children and adolescents aged 7 to 18 years (10 studies31,32,41,46,48,53,59,61-63).
No significant difference in results was observed between age groups enrolled. For younger children, all 3 studies focused on CBT and reported consistent statistically significant benefits for anxiety symptoms in 257,68 of 357,66,68 studies. Two studies reported on response, and both reported statistically significant differences favoring CBT.57,66 One study reported on remission57 and 1 reported on functioning,68 and both suggested statistically significant differences favoring CBT. One66 of 266,68 studies reported statistically significant differences favoring CBT for loss of diagnosis.
For studies enrolling only adolescents, 3 studies42,43,54 reported on CBT and 1 reported on escitalopram.70 Two42,43 of the 3 CBT studies42,43,54 reported consistent statistically significant improvement in anxiety symptoms, response, and remission; 1 reported no statistically significant differences.54 Only 1 CBT study reported on loss of diagnosis and found no statistically significant differences.54 Two studies reported on functioning, and neither consistently found statistically significant differences across a range of outcome measures.43,54 The escitalopram study reported improvement in symptoms and response.70
Harms of Treatment
Key Question 5. What are the harms of treatment (cognitive behavioral therapy or pharmacotherapy) in children and adolescents who are treated for anxiety?
Eleven good- or fair-quality studies (described in 22 articles) that addressed benefits also addressed harms (n = 1293). In the JAMA Supplement, key characteristics of included studies for harms are provided in eTable 20, detailed outcomes are provided in eTables 21 and 22, and results from meta-analyses are provided in eFigures 18 and 19. Outcomes reported include (1) suicide-related harms, (2) withdrawal due to adverse events, (3) and serious adverse events. Regarding suicide-related harms, 2 CBT studies reported on suicidal ideation, attempts, or self-harm behavior.32-40,54 One study of 60 participants54 reported that 2 participants in the wait-list control group only withdrew from the study because of risk of suicide by 17 weeks. A second child-focused study comparing CBT with placebo reported on self-harm behavior without suicidal attempt (1/139 [0.7%] vs 0/76 [0%]), suicidal ideation (5/139 [3.6%] vs 1/76 [1.3%]), and suicidal attempts (no event in either group) by 12 weeks.32-40 Three pharmacotherapy studies reported on suicide-related harms at the end of treatment at 8 to 12 weeks (duloxetine,41 escitalopram,70 and sertraline32-40). No study reported on suicide deaths, 2 studies reported on suicide attempts (1/26 events for escitalopram vs 0/25 events for placebo;70 no event occurred for sertraline or placebo in 1 study32-40), 3 studies reported on suicidal ideation or worsening of suicidality (1/135 for duloxetine vs 0/137 for placebo;41 6/26 for escitalopram vs 2/25 for placebo;70 0/133 for sertraline vs 1/76 for placebo32-40), and 2 studies reported on self-injurious behavior (2/26 for escitalopram vs 1/25 for placebo;]]70]] 1/133 for sertraline vs 0/76 for placebo32-40). Suicide-related harms were rare, and the differences between treatment and placebo groups were not statistically significantly different.
Regarding withdrawal due to adverse events, the pooled RR for CBT trials was 0.39 (95% CI, 0.08 to 1.87; n = 372; 4 studies32-40,43,53,54). The pooled RR across all pharmacotherapy trials was 1.72 (95% CI, 0.57 to 5.18; n = 734; 5 RCTs32-41,48-51,62,70).
For both CBT and pharmacotherapy, serious adverse events were rare and the differences between treatment and placebo groups were not statistically significantly different.
Findings Within Age Groups
No study reported on harms in young children. Results for studies of adolescents were consistent with results for the overall body of evidence: outcomes were rare and differences between treatment and comparison groups were not statistically significant.
This systematic review evaluated screening for anxiety in children and adolescents. Table 3 summarizes the evidence, including strength-of-evidence ratings. No study reported on the direct benefits or harms of screening. The discussion below focuses on the indirect evidence from studies describing test accuracy, benefits of treatment, and harms of treatment. Two of the most widely used screeners (ie, Screen for Anxiety Related Emotional Disorders and the Social Phobia Inventory) were reasonably accurate, leading to low-to-moderate strength of evidence.
Consistent, precise, statistically significant differences for most anxiety outcomes for CBT and pharmacotherapy led to strength-of-evidence ratings of moderate for benefit for nearly all outcomes. Treatment studies covered a wide range of ages, from preschool through adolescence, although 4 studies focused exclusively on adolescents (13-20 years42,43,54,70). Studies focusing on younger children aged 3 to 7 years57,66,68 were consistent with the overall findings in demonstrating benefits for symptoms and clinical response.
Few CBT trials reported on harm outcomes leading to a strength-of-evidence rating of insufficient. The evidence suggests that suicide-related harms, serious adverse events, and withdrawal due to adverse events are rare in pharmacotherapy studies but more frequent in the treatment group; thus, strength of evidence for pharmacotherapy was rated as low for harms.
Few studies reported analyses for populations of interest. Studies reporting on analyses of anxiety symptoms consistently reported no differences in effect of treatment by age, but there is insufficient evidence available on effect of treatment on anxiety symptoms by race or ethnicity.
This review has several limitations. First, no available study compared screening with no screening. Second, only limited evidence was available on long-term outcomes and on test accuracy and treatment in children. Third, the review was limited to CBT and drugs approved for pediatric use by the US Food and Drug Administration.
Indirect evidence suggested that some screening instruments were reasonably accurate for detecting anxiety. CBT and pharmacotherapy were associated with benefits; no statistically significant association with harms was reported.
Source: This article was first published online in the Journal of the American Medical Association on October 11, 2022 (JAMA. 2022;328(14):1445-1455. doi:10.1001/jama.2022.16303).
Conflict of Interest Disclosures: Dr Vander Schaaf reported that she is a Fellow of the American Academy of Pediatrics and member of American Academy of Pediatrics CATCH Committee. No other disclosures were reported.
Funding/Support: This study was funded under contract HHSA-290-2015-00011-I, Task Order 15, and Contract 75Q80120D00007, Task Order 05, from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services (HHS), under a contract to support the US Preventive Services Task Force (USPSTF).
Role of the Funder/Sponsor: Investigators worked with USPSTF members and AHRQ staff to develop the scope, analytic framework, and key questions for this review. AHRQ had no role in study selection, quality assessment, or synthesis. AHRQ staff provided project oversight, reviewed the report to ensure that the analysis met methodological standards, and distributed the draft for peer review. Otherwise, AHRQ had no role in the conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript findings. The opinions expressed in this document are those of the authors and do not represent the official position of AHRQ or HHS.
Additional Contributions: We acknowledge the following individuals for their contributions to this project: AHRQ staff Iris Mabry-Hernandez, MD, MPH, and Tracy Wolf, MD, MPH; current and former members of the USPSTF who contributed to topic deliberations; and RTI International–University of North Carolina Evidence-based Practice Center staff Christiane Voisin, MSLS, Candi Wines, MPH, Nila A. Sathe, MA, MLIS, Carol Woodell, BSPH, Sharon Barrell, MA, Staci Rachman, BA, Sarah Barringer, Michelle Bogus, Teyonna Downing, and Loraine Monroe. USPSTF members, peer reviewers, and federal partner reviewers did not receive financial compensation for their contributions.
Additional Information: A draft version of the full evidence report underwent external peer review from 4 content experts (Gregory Simon, MD, MPH, University of Washington; Joan Asarnow, PhD, University of California, Los Angeles; Natalie Cort, PhD, William James College; and Raquel Halfond, PhD, American Psychological Association) and 1 federal partner reviewer (Erin Abramsohn, DrPH, Centers for Disease Control and Prevention). Comments from reviewers were presented to the USPSTF during its deliberation of the evidence and were considered by the authors in preparing the final evidence review.
1. US Department of Commerce. 2020 National Survey of Children’s Health: Topical Frequencies. US Census Bureau; 2021.
2. Beesdo K, Bittner A, Pine DS, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007;64(8):903-912. doi:10.1001/archpsyc.64.8.903
3. Beesdo-Baum K, Höfler M, Gloster AT, et al. The structure of common mental disorders: a replication study in a community sample of adolescents and young adults. Int J Methods Psychiatr Res. 2009;18(4):204-220. doi:10.1002/mpr.293
4. Tandon M, Cardeli E, Luby J. Internalizing disorders in early childhood: a review of depressive and anxiety disorders. Child Adolesc Psychiatr Clin N Am. 2009;18(3):593-610. doi:10.1016/j.chc.2009.03.004
5. Bittner A, Egger HL, Erkanli A, Jane Costello E, Foley DL, Angold A. What do childhood anxiety disorders predict? J Child Psychol Psychiatry. 2007;48(12):1174-1183. doi:10.1111/j.1469-7610.2007.01812.x
6. Ezpeleta L, Keeler G, Erkanli A, Costello EJ, Angold A. Epidemiology of psychiatric disability in childhood and adolescence. J Child Psychol Psychiatry. 2001;42(7):901-914. doi:10.1111/1469-7610.00786
7. Copeland WE, Angold A, Shanahan L, Costello EJ. Longitudinal patterns of anxiety from childhood to adulthood: the Great Smoky Mountains Study. J Am Acad Child Adolesc Psychiatry. 2014;53(1):21-33. doi:10.1016/j.jaac.2013.09.017
8. Woodward LJ, Fergusson DM. Life course outcomes of young people with anxiety disorders in adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40(9):1086-1093. doi:10.1097/00004583- 200109000-00018
9. US Preventive Services Task Force. US Preventive Services Task Force Procedure Manual. Published 2021. Accessed August 16, 2022. https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual
10. Viswanathan M, Wallace I, Cook Middleton J, et al. Screening for Depression, Anxiety, and Suicide Risk in Children and Adolescents: An Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 221. Agency for Healthcare Research and Quality; 2022. AHRQ publication 22-05293-EF-1.
11. Wang Z, Whiteside S, Sim L, et al. Anxiety In Children. Report No. 17-EHC023-EF. Comparative Effectiveness Reviews No. 192. Agency for Healthcare Research and Quality. Published 2017. Accessed August 31, 2022. https://www.effectivehealthcare.ahrq.gov/reports/final.cfm
12. United Nations Development Programme. Human Development Report 2019: Beyond Income, Beyond Averages, Beyond Today: Inequalities in Human Development in the 21st Century. Published 2019. Accessed August 31, 2022. https://hdr.undp.org/content/humandevelopment-report-2019
13. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
14. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi:10.1136/bmj.i4919
15. Whiting P, Savović J, Higgins JP, et al; ROBIS Group. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225-234. doi:10.1016/j.jclinepi.2015.06.005
16. Whiting PF, Rutjes AW, Westwood ME, et al; QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536. doi:10.7326/0003-4819-155-8-201110180-00009
17. Comprehensive Meta-analysis. Version 3. Biostat; 2013. Accessed September 16, 2022. https://www.meta-analysis.com/
18. Deeks J, Higgins J, Altman DG; Cochrane Statistical Methods Group. Analysing data and undertaking meta-analyses. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V, eds. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane. Published 2022. Accessed August 31, 2022. https://training.cochrane.org/handbook
19. US Preventive Services Task Force. US Preventive Services Task Force Procedure Manual: appendix VI: criteria for assessing internal validity of individual studies. Published 2017. https://www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-appendix-vi-criteria-assessing-internal-validity-individual-studies
20. Viswanathan M, Wallace IF, Cook Middleton JC, et al. Screening for depression and suicide risk in children and adolescents: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. Published online October 11, 2022. doi:10.1001/jama.2022.16310
21. Bailey KA, Chavira DA, Stein MT, Stein MB. Brief measures to screen for social phobia in primary care pediatrics. J Pediatr Psychol. 2006;31(5):512-521. doi:10.1093/jpepsy/jsj044
22. Canals J, Hernández-Martínez C, Cosi S, Domènech E. Examination of a cutoff score for the Screen for Child Anxiety Related Emotional Disorders (SCARED) in a non-clinical Spanish population. J Anxiety Disord. 2012;26(8):785-791. doi:10.1016/j.janxdis.2012.07.008
23. Garcia-Lopez LJ, Sáez-Castillo AJ, Beidel D, La Greca AM. Brief measures to screen for social anxiety in adolescents. J Dev Behav Pediatr. 2015;36(8):562-568. doi:10.1097/DBP.0000000000000213
24. Johnson JG, Harris ES, Spitzer RL, Williams JBW. The patient health questionnaire for adolescents: validation of an instrument for the assessment of mental disorders among adolescent primary care patients. J Adolesc Health. 2002;30(3):196-204. doi:10.1016/S1054-139X(01)00333-0
25. Muris P, Merckelbach H, Kindt M, et al. The utility of Screen for Child Anxiety Related Emotional Disorders (SCARED) as a tool for identifying children at high risk for prevalent anxiety disorders. Anxiety Stress Coping. 2001;14(3):265-283. doi:10.1080/10615800108248357
26. O’Connor S, Ferguson E, Carney T, House E, O’Connor RC. The development and evaluation of the paediatric index of emotional distress (PI-ED). Soc Psychiatry Psychiatr Epidemiol. 2016;51(1):15-26. doi:10.1007/s00127-015-1134-y
27. Queen AH, Ehrenreich-May J, Hershorin ER. Preliminary validation of a screening tool for adolescent panic disorder in pediatric primary care clinics. Child Psychiatry Hum Dev. 2012;43(2):171-183. doi:10.1007/s10578-011-0256-z
28. Ranta K, Kaltiala-Heino R, Rantanen P, Tuomisto MT, Marttunen M. Screening social phobia in adolescents from general population: the validity of the Social Phobia Inventory (SPIN) against a clinical interview. Eur Psychiatry. 2007;22(4):244-251. doi:10.1016/j.eurpsy.2006.12.002
29. Ranta K, Kaltiala-Heino R, Rantanen P, Marttunen M. The Mini-Social Phobia Inventory: psychometric properties in an adolescent general population sample. Compr Psychiatry. 2012;53(5):630-637. doi:10.1016/j.comppsych.2011.07.007
30. Tsai CF, Wang SJ, Juang KD, Fuh JL. Use of the Chinese (Taiwan) version of the Social Phobia Inventory (SPIN) among early adolescents in rural areas: reliability and validity study. J Chin Med Assoc. 2009;72(8):422-429. doi:10.1016/S1726-4901(09)70399-5
31. Ishikawa SI, Kikuta K, Sakai M, Mitamura T, Motomura N, Hudson JL. A randomized controlled trial of a bidirectional cultural adaptation of cognitive behavior therapy for children and adolescents with anxiety disorders. Behav Res Ther. 2019;120:103432. doi:10.1016/j.brat.2019.103432
32. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753-2766. doi:10.1056/NEJMoa0804633
33. Albano AM, Comer JS, Compton SN, et al. Secondary outcomes from the child/adolescent anxiety multimodal study: implications for clinical practice. Evid Based Pract Child Adolesc Ment Health. 2018;3(1):30-41. doi:10.1080/23794925.2017.1399485
34. Taylor JH, Lebowitz ER, Jakubovski E, Coughlin CG, Silverman WK, Bloch MH. Monotherapy insufficient in severe anxiety? predictors and moderators in the child/adolescent anxiety multimodal study. J Clin Child Adolesc Psychol. 2018;47(2):266-281. doi:10.1080/15374416.2017.1371028
35. Compton SN, Peris TS, Almirall D, et al. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J Consult Clin Psychol. 2014;82(2):212-224. doi:10.1037/a0035458
36. Caporino NE, Read KL, Shiffrin N, et al. Sleep-related problems and the effects of anxiety treatment in children and adolescents. J Clin Child Adolesc Psychol. 2017;46(5):675-685. doi:10.1080/15374416.2015.1063429
37. Sanchez AL, Comer JS, Coxe S, et al. The effects of youth anxiety treatment on school impairment: differential outcomes across CBT, sertraline, and their combination. Child Psychiatry Hum Dev. 2019;50(6):940-949. doi:10.1007/s10578-019-00896-3
38. Rynn MA, Walkup JT, Compton SN, et al. Child/adolescent anxiety multimodal study: evaluating safety. J Am Acad Child Adolesc Psychiatry. 2015;54(3):180-190. doi:10.1016/j.jaac.2014.12.015
39. Gordon-Hollingsworth AT, Becker EM, Ginsburg GS, et al. Anxiety disorders in Caucasian and African American children: a comparison of clinical characteristics, treatment process variables, and treatment outcomes. Child Psychiatry Hum Dev. 2015;46(5):643-655. doi:10. 1007/s10578-014-0507-x
40. Ginsburg GS, Kendall PC, Sakolsky D, et al. Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS. J Consult Clin Psychol. 2011;79(6):806- 813. doi:10.1037/a0025933
41. Strawn JR, Prakash A, Zhang Q, et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2015;54(4):283-293. doi:10.1016/j.jaac.2015.01.008
42. Salzer S, Stefini A, Kronmüller KT, et al. Cognitive-behavioral and psychodynamic therapy in adolescents with social anxiety disorder: a multicenter randomized controlled trial. Psychother Psychosom. 2018;87(4):223-233. doi:10.1159/000488990
43. Stjerneklar S, Hougaard E, McLellan LF, Thastum M. A randomized controlled trial examining the efficacy of an internet-based cognitive behavioral therapy program for adolescents with anxiety disorders. PLoS One. 2019;14(9):e0222485. doi:10.1371/journal.pone.0222485
44. Cornacchio D, Furr JM, Sanchez AL, et al. Intensive group behavioral treatment (IGBT) for children with selective mutism: a preliminary randomized clinical trial. J Consult Clin Psychol. 2019;87(8):720-733. doi:10.1037/ccp0000422
45. Cobham VE, Filus A, Sanders MR. Working with parents to treat anxiety-disordered children: a proof of concept RCT evaluating Fear-less Triple P. Behav Res Ther. 2017;95:128-138. doi:10.1016/j.brat.2017.06.004
46. Ginsburg GS, Pella JE, Pikulski PJ, Tein JY, Drake KL. School-Based Treatment for Anxiety Research Study (STARS): a randomized controlled effectiveness trial. J Abnorm Child Psychol. 2020;48(3):407-417. doi:10.1007/s10802-019-00596-5
47. Asbrand J, Heinrichs N, Schmidtendorf S, Nitschke K, Tuschen-Caffier B. Experience versus report: where are changes seen after exposure-based cognitive-behavioral therapy? a randomized controlled group treatment of childhood social anxiety disorder. Child Psychiatry Hum Dev. 2020;51(3):427-441. doi:10.1007/s10578-019-00954-w
48. Pine DS, Walkup JT, Labellarte MJ, et al; Research Units on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001;344(17):1279-1285. doi:10.1056/NEJM200104263441703
49. Walkup JT, Labellarte MJ, Riddle MA, et al; Research Units on Pediatric Psychopharmacology Anxiety Study Group. Searching for moderators and mediators of pharmacological treatment effects in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(1):13-21. doi:10.1097/00004583-200301000-00006
50. Ginsburg GS, Riddle MA, Davies M. Somatic symptoms in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2006;45(10):1179-1187. doi:10.1097/01.chi0000231974.43966.6e
51. Reinblatt SP, DosReis S, Walkup JT, Riddle MA. Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19(2):119-126. doi:10.1089/cap.2008.040
52. Thirlwall K, Cooper PJ, Karalus J, Voysey M, Willetts L, Creswell C. Treatment of child anxiety disorders via guided parent-delivered cognitive-behavioural therapy: randomised controlled trial. Br J Psychiatry. 2013;203(6):436-444. doi:10.1192/bjp.bp.113.126698
53. Perrin S, Bevan D, Payne S, Bolton D. GAD-specific cognitive behavioral treatment for children and adolescents: a pilot randomized controlled trial. Cognit Ther Res. 2019;43:1051-1064. doi:10.1007/s10608-019-10020-3
54. Waite P, Marshall T, Creswell C. A randomized controlled trial of internet-delivered cognitive behaviour therapy for adolescent anxiety disorders in a routine clinical care setting with and without parent sessions. Child Adolesc Ment Health. 2019;24(3):242-250. doi:10.1111/camh.12311
55. Lau WY, Chan CK-y, Li JC, Au TK. Effectiveness of group cognitive-behavioral treatment for childhood anxiety in community clinics. Behav Res Ther. 2010;48(11):1067-1077. doi:10.1016/j.brat.2010.07.007
56. Lyneham HJ, Rapee RM. Evaluation of therapist-supported parent-implemented CBT for anxiety disorders in rural children. Behav Res Ther. 2006;44(9):1287-1300. doi:10.1016/j.brat.2005.09.009
57. Rudy BM, Zavrou S, Johnco C, Storch EA, Lewin AB. Parent-led exposure therapy: a pilot study of a brief behavioral treatment for anxiety in young children. J Child Fam Stud. 2017;26(9):2475-2484. doi:10.1007/s10826-017-0772-y
58. Villabø MA, Narayanan M, Compton SN, Kendall PC, Neumer S-P. Cognitive-behavioral therapy for youth anxiety: an effectiveness evaluation in community practice. J Consult Clin Psychol. 2018;86(9):751-764. doi:10.1037/ ccp0000326
59. Arendt K, Thastum M, Hougaard E. Efficacy of a Danish version of the Cool Kids program: a randomized wait-list controlled trial. Acta Psychiatr Scand. 2016;133(2):109-121. doi:10.1111/acps.12448
60. Öst L-G, Cederlund R, Reuterskiöld L. Behavioral treatment of social phobia in youth: does parent education training improve the outcome? Behav Res Ther. 2015;67:19-29. doi:10.1016/j.brat.2015.02.001
61. Black B, Uhde TW. Treatment of elective mutism with fluoxetine: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 1994;33(7):1000-1006. doi:10.1097/00004583-199409000-00010
62. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(4):415-423. doi:10.1097/01.CHI. 0000037049.04952.9F
63. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158(12):2008-2014. doi:10.1176/appi.ajp.158.12.2008
64. Barrett PM, Dadds MR, Rapee RM. Family treatment of childhood anxiety: a controlled trial. J Consult Clin Psychol. 1996;64(2):333-342. doi:10.1037/0022-006X.64.2.333
65. Holmes MC, Donovan CL, Farrell LJ, March S. The efficacy of a group-based, disorder-specific treatment program for childhood GAD—a randomized controlled trial. Behav Res Ther. 2014;61:122-135. doi:10.1016/j.brat.2014.08.002
66. Hirshfeld-Becker DR, Masek B, Henin A, et al. Cognitive behavioral therapy for 4- to 7-year-old children with anxiety disorders: a randomized clinical trial. J Consult Clin Psychol. 2010;78(4):498-510. doi:10.1037/a0019055
67. Shortt AL, Barrett PM, Fox TL. Evaluating the FRIENDS program: a cognitive-behavioral group treatment for anxious children and their parents. J Clin Child Psychol. 2001;30(4):525-535. doi:10.1207/S15374424JCCP3004_09
68. Donovan CL, March S. Online CBT for preschool anxiety disorders: a randomised control trial. Behav Res Ther. 2014;58:24-35. doi:10.1016/j.brat.2014.05.001
69. Sánchez-García R, Olivares Rodríguez J. Effectiveness of a program for early detection/intervention in children/adolescents with generalized social phobia. An Psicol. Published December 2009. Accessed August 31, 2022. https://www.researchgate.net/publication/46171908_Effectiveness_of_a_program_for_early_detectionintervention_in_childrenadolescents_with_generalized_social_phobia
70. Strawn JR, Mills JA, Schroeder H, et al. Escitalopram in adolescents with generalized anxiety disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychiatry. 2020;81(5):20m13396. doi:10.4088/JCP.20m13396
71. O’Connor E, Senger CA, Henninger M, Gaynes BN, Coppola E, Soulsby Weyrich M. US Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Interventions to Prevent Perinatal Depression: A Systematic Evidence Review for the US Preventive Services Task Force. Agency for Healthcare Research and Quality; 2019.
72. Mammarella IC, Donolato E, Caviola S, Giofrè D. Anxiety profiles and protective factors: a latent profile analysis in children. Pers Individ Dif. 2018;124:201-208. doi:10.1016/j.paid.2017.12.017
73. Osimo EF, Stochl J, Zammit S, Lewis G, Jones PB, Khandaker GM. Longitudinal population subgroups of CRP and risk of depression in the ALSPAC birth cohort. Compr Psychiatry. 2020;96:152143. doi:10.1016/j.comppsych.2019.152143
Evidence reviews for the US Preventive Services Task Force (USPSTF) use an analytic framework to visually display the key questions that the review will address to allow the USPSTF to evaluate the effectiveness and safety of a preventive service. The questions are depicted by linkages that relate interventions and outcomes. Refer to the USPSTF Procedure Manual for interpretation of the analytic framework.9
Reasons for exclusion: Population: Study was not conducted in an included population. Comparator: Study did not use an included comparator. Intervention: Study did not use an included intervention. Outcomes: Study did not report relevant outcomes. Design: Study did not use an included design. Other target condition: Study reported on depression or suicide risk. Quality: Study was poor quality. Setting: Study was not conducted in settings representative of primary care. Publication type: Publication was a commentary. Country: Study was not conducted in a country relevant to US practice. Protocol or ongoing study: Study was a protocol or ongoing study and did not report eligible outcomes. Language: Study was not in English. Duplicate: Study was a duplicate of other studies in the review. Superseded by publication: Study findings were wholly superseded by another publication. KQ indicates key question.
a Combined searches were conducted on anxiety, depression, and suicide risk. Results for depression and suicide risk are presented in a separate publication.20
b Study may address more than 1 KQ.
|Condition||Screening||Age range, y||No. of studies||Sensitivity||Specificity|
|Generalized anxiety disorder||PHQ-A||13–18||124||0.50||0.98|
|Panic disorder||ANSQ (various thresholds)||12-18||127||1.00||0.47-0.65|
|Separation anxiety disorder||SCARED-SAD subscale||7-14||125||0.88||0.73|
|Social anxiety disorder||SCARED-social phobia scale
|SAS (various thresholds)||8-18||221,23||0.75-0.93||0.74-0.80|
|SPIN/Mini-SPIN (various thresholds)||12-17||328-30||0.80-0.86||0.77-0.85|
|SWQ (various thresholds)||13-17||121||0.67-0.83||0.84-0.94|
|Any anxiety disorder||PHQ-A||13-18||124||0.50||0.98|
Abbreviations: ANSQ, Autonomic Nervous System Questionnaire; PHQ-A, Patient Health Questionnaire for Adolescents; PI-ED, Paediatric Index of Emotional Distress; SAS, Social Anxiety Scale; SAS-A, Social Anxiety Scale for Adolescents; SCARED, Screen for Child Anxiety Related Disorders; SCARED-GAD, Screen for Child Anxiety Related Disorders–Generalized Anxiety Disorder; SCARED-SAD, Screen for Child Anxiety Related Disorders–Separation Anxiety Disorder; SPAI, Social Phobia and Anxiety Inventory; SPIN, Social Phobia Inventory; SWQ, Social Worries Questionnaire.
|Intervention (mode of delivery for psychotherapy interventions)||Time of outcome measurement (from baseline)||Outcome measure, range, threshold||Outcome range||Outcome threshold indicating clinically meaningful effect||Treatment range at follow-up||Comparator range at follow-up||No. of studies
(No. of participants)
|Pooled effect size
(95% CI); I2
|Change in symptoms|
|Individual-, group/child-, parent-, or child + parent-focused (in-person, email, telephone, or internet)||4-17 wk||Primary diagnosis of ADIS-CSR or all diagnoses||0-8||Score of 4 (moderate degree of impairment) or greater indicates a clinical diagnosis||1.9-4.2||3.6-6.2||1131,43-45,53,54,57,59,65,68,73 (579)||Mean difference, −2.01 (−2.74 to −1.29)
I2 = 83%
|6-17 wk||SCAS-C||0-114||Cutoffs vary by age and sex, from 33 to 50 (higher scores represent worse outcomes)||21.6-34.9||29.4-42.1||931,43,45,52,54-56,59,65 (668)||Mean difference, −7.81 (−10.99 to −4.63)
|6-17 wk||SCAS-P||0-114||Cutoffs vary by age and sex, from 33 to 50 (higher scores represent worse outcomes)||18.8-33.1||24.2-41.3||931,43,45,52,54-56,59,65 (652)||Mean difference, −6.06 (−9.58 to −2.56)
|Individual/child-focused or parent-led (in-person)||5-12 wk||CGI-S||1-7||Score of 2: borderline ill; 3, mildly ill; 4, moderate illness||2.0-4.0||3.3-4.2||332-40,46,57 (453)||Mean difference, −0.60 (−1.14 to −0.06)
|Individual-, group/child-, or child + parent-focused (in-person)||12 wk||MASC||0-117||Cutoff scores may not be possible to establish||40.9-48.8||42.9-54.7||332-40,58,60,73 (435)||Mean difference, −4.66 (−9.66 to 0.34)
|Individual-, group/child-, or child + parent-focused (in-person, email, telephone, or internet)||10-12 wk||RCMAS||0-28||Score ≥19 indicates clinically significant levels of anxiety||6.6-10.9||9.8-15.7||356,64,67 (241)||Mean difference, −3.08 (−5.91 to −0.24)
|Fluoxetine, fluvoxamine, duloxetine, escitalopram, or sertraline||8-12 wk||PARS||0-25||Score >11.5 discriminates youth without anxiety disorders from those with anxiety disorders||8.1-9.8||9.3-15.9||532-41,48-51,62,70 (726)||Mean difference, −4.0 (−5.5 to −2.5)
I2 = 81%
|Duloxetine, escitalopram, or sertraline||8-12 wk||CGI-S||1-7||Score of 2: borderline ill; 3, mildly ill; 4, moderate illness||2.4-3.0||3.1-3.9||432-41,63,70 (550)||Mean difference, −0.84 (−1.13 to −0.55)
I2 = 75%
|Clinical response, remission, and loss of diagnosis|
|Individual-, group/child-, parent-, or child + parent-focused (in-person)||4 wk to 6 mo||Proportion with a clinical response (CGI score of 1 or 2)||0%-100%||CGI-I scores of 1 and 2 indicate moderate marked improvement, proportion threshold unclear||40%-83%||0%-37%||632,44,46,57,66 (606)||RR, 1.89 (1.17 to 3.05)
|Individual-, group/child-, parent-, or child + parent-focused (in-person, email, telephone, or internet)||8-16 wk||Remission from anxiety symptoms on SCAS-C||0%-100%||Unclear; “clinically significant change”||43%-62%||6%-38%||431,43,56,59 (321)||RR, 2.68 (1.48 to 4.88)
|8-16 wk||Loss of all anxiety diagnoses||0%-100%||No diagnosis following a structured clinical interview||15%-80%||0%-35%||1531,43,45,46,52-54,58,59,64-68 (1414)||RR, 3.09 (1.98 to 4.80)
I2 = 65%
|6 wk to 12 mo||Loss of primary anxiety diagnosis||0%-100%||No diagnosis following a structured clinical interview||7%-80%||0%-43%||1331,43-46,52-54,58-60,65,68,73 (1079)||RR, 3.02 (1.84 to 4.95)
|Escitalopram, fluoxetine, or sertraline||8-12 wk||Proportion with a clinical response (CGI score of 1 or 2)||0%-100% for proportion||CGI-I scores of 1 and 2 indicate moderate marked improvement, proportion threshold unclear||50%-91%||9%-44%||532-40,61-63,70 (370)||RR, 2.11 (1.58 to 2.98)
|Individual-, group/child-, parent-, or child + parent-focused (in-person, telephone, internet, or combination)||8-12 wk||CAIS||0-81||Score <7: no anxiety diagnosis||6.4-21.8||15.2-19.6||333,52,54 (403)||Mean difference, −2.23 (−5.88 to 1.43)
|4-12 wk||CGAS||1-100||Score >70: no clinically significant functional impairment
Score <41: major impairment to functioning in several areas
|53.6-82.1||52.5-61.9||832-40,44,46,53,54,58,65,68 (811)||Mean difference, 7.54 (2.84 to 12.23)
|Duloxetine, fluoxetine, or sertraline||10-12 wk||CGAS||1-100||Score >70: no clinically significant functional impairment
Score <41: major impairment to functioning in several areas
|62.1-68.5||59.3-64.6||332-41,62 (551)||Mean difference, 5.14 (3.21 to 7.08)
Abbreviations: ADIS-CSR, Anxiety Disorders Interview Schedule–Clinician Severity Rating; CAIS, Children’s Anxiety Impact Scale; CBT, cognitive behavioral therapy; CGAS, Children’s Global Assessment Scale; CGI, Clinical Global Impression scale; CGI-I, Clinical Global Impression–Improvement; CGI-S, Clinical Global Impression–Severity; MASC, Multidimensional Anxiety Scale for Children; PARS, Pediatric Anxiety Rating Scale; RCMAS, Revised Children’s Manifest Anxiety Scale; RR, relative risk; SCAS, Spence Children’s Anxiety Scale; SCAS-C, Spence Children’s Anxiety Scale–Child-rated; SCAS-P, Spence Children’s Anxiety Scale–Parent-rated.
|No. of studies, study designs||No. of participants||Summary of findings||Consistency, precision||Limitations||Strength of evidence||Applicability|
|KQ1: Benefits of screening|
|KQ2: Accuracy of screening instruments|
|10 Studies21-30||3260||Varies by screener, threshold, and condition
Sensitivity range, 0.34-1.00
Specificity range, 0.47-0.99
|Consistency unknown for individual screeners; imprecise||No replication of results for specific thresholds and screeners; unclear whether thresholds were established a priori or whether index and reference standard results were blinded||Low to moderate (varies by instrument)||Participants were primarily adolescents, but school-aged children were included in 4 studies
Applicable to both primary care and school-based settings
A variety of different screeners were used, of which only 2 (SCARED and SPIN) are used widely in practice for detecting anxiety
|KQ3: Harms of screening|
|KQ4: Benefits of treatment|
|29 RCTs (22 on CBT; 6 on pharmacotherapy; 1 on CBT, sertraline, and combination)31-70||2805||CBT: Statistically significant differences favoring CBT on several pooled measures of symptom improvement
Statistically significant improvement on CGAS but not on CAIS
Pharmacotherapy: Statistically significant differences favoring pharmacotherapy on pooled measures of symptom improvement and response
Statistically significant differences favoring pharmacotherapy on pooled CGAS but not on other measures of functioning
|Mostly consistent; mostly precise||Potential for bias from attrition
Additionally, CBT studies cannot mask treatments, leading to the potential for bias in outcomereporting
|Moderate for anxiety symptoms, response, remission, and loss of diagnosis; low for functioning||15 CBT studies targeted any anxiety disorders; only 1 pharmacotherapy study targeted any anxiety disorders
Studies addressed youth aged 3 to 20 y, but 11 were conducted exclusively in adolescents
Psychotherapy studies were limited to CBT; pharmacotherapy studies were limited to drugs with FDA approval for pediatric use
|KQ5: Harms of treatment|
|11 RCTs (4 on CBT; 6 on pharmacotherapy; 1 on CBT, sertraline, and combination)32-43,48-51,53,54,61-63,70||1293||Psychotherapy: Inconsistent results on suicide-related events; harms were events and were not statistically significant
Pharmacotherapy: More suicide-related events and withdrawals due to adverse events in the pharmacotherapy group, but harms were rare and not statistically significant
|Consistent to mostly consistent; imprecise||CBT interventions cannot mask treatment, leading to the potential for bias in outcome reporting||Psychotherapy: insufficient evidence
Pharmacotherapy: low for harms
|Two of 4 CBT studies included any anxiety disorders; 1 of 7 pharmacotherapy studies included any anxiety disorders
Studies addressed children aged 5 to 20 y, but 4 were conducted exclusively in adolescents
Psychotherapy studies were limited to CBT; pharmacotherapy studies were limited to drugs with FDA approval for pediatric use
Abbreviations: CAIS, Children’s Anxiety Impact Scale; CBT, cognitive behavioral therapy; CGAS, Children’s Global Assessment Scale; FDA, US Food and Drug Administration; KQ, key question; NA, not applicable; RCT, randomized clinical trial; SCARED, Screen for Anxiety Related Emotional Disorders; SPIN, Social Phobia Inventory.